Atalanta Sosnoff Capital LLC Decreases Stock Holdings in Eli Lilly and Company $LLY

Atalanta Sosnoff Capital LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 1.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,896 shares of the company’s stock after selling 1,413 shares during the period. Eli Lilly and Company accounts for 2.8% of Atalanta Sosnoff Capital LLC’s portfolio, making the stock its 9th largest holding. Atalanta Sosnoff Capital LLC’s holdings in Eli Lilly and Company were worth $141,746,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Tillman Hartley LLC raised its position in Eli Lilly and Company by 12.6% in the fourth quarter. Tillman Hartley LLC now owns 706 shares of the company’s stock worth $759,000 after acquiring an additional 79 shares during the period. Allianz SE grew its stake in shares of Eli Lilly and Company by 5.9% during the 4th quarter. Allianz SE now owns 41,916 shares of the company’s stock valued at $45,046,000 after acquiring an additional 2,326 shares during the period. Gerber Kawasaki Wealth & Investment Management grew its stake in shares of Eli Lilly and Company by 23.3% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 12,075 shares of the company’s stock valued at $12,986,000 after acquiring an additional 2,280 shares during the period. Summit Financial LLC grew its stake in shares of Eli Lilly and Company by 2.5% during the 4th quarter. Summit Financial LLC now owns 15,249 shares of the company’s stock valued at $16,388,000 after acquiring an additional 372 shares during the period. Finally, M1 Capital Management LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. M1 Capital Management LLC now owns 548 shares of the company’s stock valued at $589,000 after acquiring an additional 15 shares during the period. 82.53% of the stock is currently owned by institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

Eli Lilly and Company Stock Down 2.1%

Eli Lilly and Company stock opened at $1,137.01 on Friday. The stock has a market capitalization of $1.07 trillion, a PE ratio of 40.39, a price-to-earnings-growth ratio of 1.27 and a beta of 0.53. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,182.73. The business has a 50 day simple moving average of $998.47 and a 200-day simple moving average of $1,016.72. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the business earned $3.34 earnings per share. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday. Bank of America increased their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Jefferies Financial Group increased their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.